Rosetta (mile)stones
Rosetta gets more clinical-stage assets with secondary purchase from pharma VC
Rosetta (mile)stones
Rosetta Capital Ltd.'s latest secondary equity acquisition fits into the firm's wheelhouse because the deal includes clinical-stage companies with upcoming catalysts.
Last week, the London life sciences venture firm
